

In the specification:

Please amend the portion of the specification beginning at page 19, line 5, and continuing to the first line of page 21 as follows:

(E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (CR1);
(E,E)-2-(benzylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);
(E,E)-2-(benzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR3);
(E,E)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);
(E,E)-2-(phenylethylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);
(E,E)-2-(phenylethylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR8);
(E,E)-2-(phenylpropylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9);
(E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);
(E,E)-2-aminothiocabonylthioacetamide-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);
(E,E)-2-aminocarbonylacetamide-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);
(E,E)-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);
(E,E)-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);
(E,E)-2-aminocarbonylacetamide-3-[3,4-bis(t-butyl dimethylsilyloxy)styryl]acrylonitrile (CR16);
(E,E)-2-aminocarbonylacetamide-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);
(E,E)-2-(benzylaminocarbonyl)-3-[[3,4-bis(t-butyl dimethylsilyloxy)styryl]]acrylonitrile (CR18);
(E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19);
(E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-[3,4-bis(t-butyl dimethylsilyloxy)styryl]acrylonitrile (CR20);
(E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21);

(*E,E*)-2-(β -ethanolaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24);
 (*E,E*)-2-(benzylaminocarbonylde)-3-(4-nitrostyryl)acrylonitrile (CR27);
 (*E,E*)-2-(3,4-dihydroxybenzylaminocarbonylde)-3-(4-nitrostyryl)acrylonitrile(CR28); and
 (*ZE,E*)-2-(1-amino-2,2-dicyanoethenyl)-3-(4-nitrostyryl)acrylonitrile (CR29).

In preferred embodiments of the present invention, the compounds of the invention include:

(*E,E*)-2-(benzylaminocarbonylde)-3-styrylacrylonitrile (CR1);
 (*E,E*)-2-(benzylaminocarbonylde)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);
 (*E,E*)-2-(benzylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR3);
 (*E,E*)-2-(benzylaminocarbonylde)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);
 (*E,E*)-2-(phenylethylaminocarbonylde)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);
 (*E,E*)-2-(phenylpropylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9);
 (*E,E*)-2-(3,4-dihydroxybenzylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);
 (*E,E*)-2-aminothiocabonylthioacetamide -3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);
 (*E,E*)-2-aminocarbonylaacetamide-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);
 (*E,E*)-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);
 (*E,E*)-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);
 (*E,E*)-2-aminocarbonylaacetamide-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);
 (*E,E*)-2-(3,4-dihydroxybenzylaminocarbonylde)-3-styrylacrylonitrile (CR19);
 (*E,E*)-2-(3,4-dihydroxybenzylaminocarbonylde)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21); and
 (*E,E*)-2-(β -ethanolaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24).

In more preferred embodiments of the present invention, the compounds of the invention include:

(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);
(*E,E*)-2-aminocarbonylacetamid~~e~~-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl~~de~~)-3-styrylacrylonitrile (CR19);
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl~~de~~)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21); and
(*E,E*)-2-(β -ethanolaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile

Please amend the section of the specification from page 26, line 8, to page 27, line 16, as follows:

(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-styrylacrylonitrile (CR1);
(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);
(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR3);
(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);
(*E,E*)-2-(phenylethylaminocarbonyl~~de~~)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);
(*E,E*)-2-(phenylethylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR8);
(*E,E*)-2-(phenylpropylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9);
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);
(*E,E*)-2-aminothiocabonylthioacetamid~~e~~-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);

(E,E)-2-aminocarbonylacetamide-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);
 (E,E)-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);
 (E,E)-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);
 (E,E)-2-aminocarbonylacetamide-3-[3,4-bis(t-butyl dimethylsilyloxy)styryl]]acrylonitrile (CR16);
 (E,E)-2-aminocarbonylacetamide-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);
 (E,E)-2-(benzylaminocarbonyl)-3-[[3,4-bis(t-butyl dimethylsilyloxy)styryl]]acrylonitrile (CR18);
 (E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19);
 (E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-[3,4-bis(t-butyl dimethylsilyloxy)styryl]]acrylonitrile (CR20);
 (E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21);
 (E,E)-2-(β -ethanolaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24);
 (E,E)-2-(benzylaminocarbonyl)-3-(4-nitrostyryl)acrylonitrile (CR27);
 (E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(4-nitrostyryl)acrylonitrile (CR28); and
 (Z,E)-2-(1-amino-2,2-dicyanoethenyl)-3-(4-nitrostyryl)acrylonitrile (CR29).

In a preferred embodiment, the present invention provides a method of inhibiting the proliferation of a cancer cell comprising administering an effective amount of a compound selected from the group of compounds:

(E,E)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);
 (E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);
 (E,E)-2-aminocarbonylacetamide-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);
 (E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19);
 (E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21); and

(E,E)-2-(β -ethanolaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile

Please amend the last paragraph on page 35 as follows:

Example 3: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11)

Please amend line 6 on page 38 as follows:

Example 7: (E,E)-2-(Benzylaminocarbonylde)-3-(3,4-dimethoxystyryl)acrylonitrile

Please amend line 20 on page 38 as follows:

Example 8: (E,E)-2-(Benzylaminocarbonylde)-3-(3,4-dihydroxystyryl)acrylonitrile

Please amend the last paragraph on page 40 as follows:

Example 12: (E,E)-2-(Benzylaminocarbonylde)-3-([3,4-bis(t-Butyldimethylsilyloxy)styryl])acrylonitrile (CR18)

Please amend line 16 on page 41 as follows:

Example 13: (E,E)-2-(Benzylaminocarbonylde)-3-(3,4-dihydroxystyryl)acrylonitrile

Please amend line 1 on page 42 as follows:

Example 14: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonylde)-3-styrylacrylonitrile

Please amend lines 16-17 on page 42 as follows:

Example 15: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonylde)-3-[3,4-bis(t-butyldimethylsilyloxy)styryl]]acrylonitrile (CR20)

Please amend lines 6-7 on page 43 as follows:

Example 16: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonylde)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21)

Please amend line 21 on page 43 as follows:

Example 17: (E,E)-2-(Benzylaminocarbonylde)-3-styrylacrylonitrile (CR1)

Please amend lines 7-8 on page 44 as follows:

Example 18: (E,E)-2-(Benzylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl) acrylonitrile (CR3)

Please amend lines 21-22 on page 45 as follows:

Example 21: (E,E)-2-(Phenylethylaminocarbonylde)-3-(3,4-dimethoxystyryl) acrylonitrile (CR5)

Please amend lines 11-12 on page 46 as follows:

Example 22: (E,E)-2-(Phenyl thylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR8)

Please amend the last paragraph on page 46 as follows:

Example 23: (E,E)-2-(Phenylpropylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9)

Please amend lines 16-17 of page 47 as follows:

Example 24: (E,E)-2- AminothiocabonylThioacetamido -3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12)

Please amend lines 5-6 of page 48 as follows:

Example 25: (E,E)-2-AminocarbonylAcetamido-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13)

Please amend lines 21-22 of page 49 as follows:

Example 28: (E,E)-2-AminocarbonylAcetamido-3-[3,4-bis(t-Butyldimethylsilyloxy)styryl)]acrylonitrile_(CR16)

Please amend line 9 of page 50 as follows:

Example 29: (E,E)-2-AminocarbonylAcetamido-3-(3,4-dihydroxystyryl)acrylonitrile

Please amend the first paragraph of page 51 as follows:

Exempl 31: (E,E)-2-(β -Ethanolaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24)

Please amend line 15 of page 51 as follows:

Example 32: (E,E)-2-(Benzylaminocarbonyl~~de~~)-3-(4-nitrostyryl)acrylonitrile (CR27)

Please amend the first full paragraph on page 52 as follows:

Example 33: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonyl~~de~~)-3-(4-nitrostyryl)acrylonitrile (CR28)

Please amend lines 21-22 of page 52 as follows:

Example 34: (~~Z~~E,E)-2-(1-Amino-2,2-dicyanoethenyl)-3-(4-nitrostyryl)acrylonitrile (CR29)